Meningitis vaccines work by training your immune system to recognize and attack specific parts of the bacteria Neisseria meningitidis before it can cause disease. There are two main types, and they use different strategies to accomplish this. Both ultimately push your body to produce antibodies that kill the bacteria by punching holes in its outer membrane, a process called complement-mediated killing.
Two Vaccine Types, Two Strategies
The vaccines available in the United States target different strains of meningococcal bacteria and use fundamentally different approaches to trigger immunity.
MenACWY vaccines (covering serogroups A, C, W, and Y) are conjugate vaccines. They contain fragments of the sugar coating that surrounds the bacteria, chemically linked to a carrier protein. The sugar coating alone is a weak trigger for lasting immunity, especially in young children. Attaching it to a protein changes the game entirely, and this is where the clever engineering comes in.
MenB vaccines (covering serogroup B) take a different approach. Serogroup B bacteria have a sugar coating that closely resembles molecules found on human nerve cells, making it a poor vaccine target. Instead, these vaccines use proteins found on the bacterial surface that help the bacteria cause disease. Bexsero contains three different bacterial proteins plus pieces of the bacterial outer membrane. Trumenba focuses on two variants of a single surface protein. Both generate antibodies that latch onto the living bacteria and mark them for destruction.
How Conjugate Vaccines Build Long-Term Memory
Your immune system has two main branches for recognizing threats. One branch, led by B cells, can spot sugar molecules on bacteria and produce antibodies against them. But this response is short-lived and doesn’t create strong memory. The other branch, led by T cells, responds to proteins and builds durable, long-lasting immunity. Conjugate vaccines essentially trick the immune system into using both branches at once.
When a conjugate vaccine is injected, immune cells in the lymph nodes take up the sugar-protein package. They break down the carrier protein into small fragments and display those fragments on their surface. Helper T cells recognize these protein fragments and become activated. Those activated T cells then help the B cells (which recognized the sugar portion) switch from producing short-lived antibodies to producing longer-lasting, more effective ones. This collaboration also creates memory B cells and memory T cells that persist for years, ready to mount a rapid response if the real bacteria show up.
Without the protein carrier, the sugar fragments would only trigger a weak, temporary antibody response with no immune memory. This is why older plain polysaccharide vaccines didn’t work well in young children and required frequent re-vaccination. The conjugate design solved both problems.
How Protein-Based MenB Vaccines Work
MenB vaccines skip the sugar approach entirely. The bacterial surface proteins they contain, including one that helps bacteria evade the immune system by binding a human protective factor, are processed directly by the immune system’s protein-recognition pathway. This naturally engages helper T cells, so no conjugation trick is needed.
After vaccination, antibodies directed against these surface proteins kill the bacteria through complement-mediated destruction. Essentially, antibodies coat the bacterial surface and recruit a cascade of blood proteins that physically puncture the bacterial membrane. In clinical studies, complete vaccination with Bexsero was 76% effective against invasive meningococcal disease and 71% effective specifically against serogroup B strains.
Protection Beyond the Individual
Meningococcal bacteria live harmlessly in the nose and throat of about 10% of the population at any given time, though this varies widely by age and setting. Transmission happens through respiratory droplets, and actual disease is a rare consequence of picking up the bacteria. Most transmission occurs among carriers who have no symptoms, with teenagers being the age group most responsible for spreading the bacteria.
Conjugate vaccines do something that protein-based vaccines may not: they reduce the ability of vaccinated people to carry the bacteria in their throats. This means vaccinated individuals are less likely to pass the bacteria to others, creating herd immunity. After the United Kingdom introduced serogroup C conjugate vaccination and specifically targeted teenagers, disease rates dropped even among unvaccinated people. This indirect protection has been one of the most important benefits of conjugate meningococcal vaccines, mirroring what has been seen with similar vaccines against other bacteria.
How Long Protection Lasts
Protection from MenACWY vaccines fades over time, which is why the vaccination schedule includes a booster. The CDC recommends a first dose at age 11 to 12, followed by a booster at 16. That booster timing is intentional: it ensures strong protection during the late teen years, when the risk of meningococcal disease peaks due to close-quarters living situations like college dormitories.
If the first dose is given between ages 13 and 15, the booster should follow at 16 to 18. If someone gets their first dose at 16 or later, no booster is needed because the single dose covers the highest-risk window.
People at ongoing increased risk, including those with a missing or nonfunctioning spleen, certain immune deficiencies, or those taking medications that block part of the immune system’s complement pathway, need boosters every five years. For children under seven in high-risk groups, the first booster comes three years after the initial series, then every five years after that.
Why Different Regions Need Different Vaccines
The dominant strains of meningococcal bacteria vary dramatically by geography. Serogroup B is the leading cause of meningococcal disease across the United States, Europe, Australia, and much of South America. In the African meningitis belt, a band of countries stretching across sub-Saharan Africa, serogroups W and C dominate. Serogroup A, once a major global threat, has been largely controlled by vaccination campaigns but still causes significant disease in China and Russia.
This geographic variation explains why vaccination strategies differ around the world. In the U.S. and Europe, comprehensive coverage means getting both MenACWY and MenB vaccines. A newer five-component vaccine targeting serogroups A, C, W, X, and Y has been developed with the African meningitis belt specifically in mind, since serogroup X is uncommon elsewhere.
Common Side Effects
The most frequent reaction to any meningitis vaccine is soreness at the injection site. For MenACWY vaccines, injection site pain occurs in roughly 31% to 69% of recipients. Fever develops in fewer than 8%. MenB vaccines tend to cause more local discomfort: injection site pain affects 82% to 98% of people who receive Bexsero, though fever is less common at 1% to 10%. The higher rate of local pain with MenB vaccines reflects the stronger inflammatory response triggered by the bacterial proteins and outer membrane vesicles in those formulations.
Serious adverse events are uncommon. In a large review of MenACWY reports, 6.5% of reported adverse events were classified as serious, though reported events represent a small fraction of all vaccinations given. For people taking complement-blocking medications, Bexsero can sometimes worsen symptoms of the underlying condition because the vaccine itself activates complement. Vaccination is ideally done before starting those medications when possible.